Juan Carlos Gómez-Esteban

Dr. Juan Carlos Gómez-Esteban

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2003 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
JZJuan J. Zarranz
Juan J. Zarranz
JAJavier Alegre
Javier Alegre
JGJuan Carlos Gómez-Esteban
Juan Carlos Gómez-Esteban
ELElena Lezcano
Elena Lezcano
RRRaquel Ros
Raquel Ros
JYJusto G. de Yebenes
Justo G. de Yebenes

12 February 2015 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JPJose‐Alberto Palma
Jose‐Alberto Palma
JGJuan Carlos Gómez-Esteban
Juan Carlos Gómez-Esteban
LNLucy Norcliffe‐Kaufmann
Lucy Norcliffe‐Kaufmann
JMJose Martinez
Jose Martinez
BTBeatriz Tijero
Beatriz Tijero
HKHoracio Kaufmann
Horacio Kaufmann

19 October 2010 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JGJuan Carlos Gómez-Esteban
Juan Carlos Gómez-Esteban
BTBeatriz Tijero
Beatriz Tijero
JSJohanne Somme
Johanne Somme
RCRoberto Ciordia
Roberto Ciordia
KBKoldo Berganzo
Koldo Berganzo
JZJuan J. Zarranz
Juan J. Zarranz

15 October 2007 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JGJuan Carlos Gómez-Esteban
Juan Carlos Gómez-Esteban
JZJuan J. Zarranz
Juan J. Zarranz
BTBeatriz Tijero
Beatriz Tijero
FVFernando Velasco
Fernando Velasco
JBJoseba Barcena
Joseba Barcena
AUAmaia Ugarte
Amaia Ugarte

10 January 2007 in European Neurology
Verified
Journal Article
Closed access
JGJuan Carlos Gómez-Esteban
Juan Carlos Gómez-Esteban
JZJ.J. Zarranz
J.J. Zarranz
ELE. Lezcano
E. Lezcano
BTB. Tijero
B. Tijero
ALA. Luna
A. Luna
IGI. Garamendi
I. Garamendi
We studied the impact of various motor and nonmotor symptoms upon quality of life in patients with Parkinson’s disease (PD). The study comprised 110 patients with PD (age: 68.6 years, course of the disease: 7.6 years). The Unified Parkinson Disease Rating Scale (UPDRS; I–IV) and Parkinson’s Disease Questionnaire (PDQ-39) were recorded. We recorded the correlations between years of disease and UPDRS IV, as well as PDQ-39 and UPDRS I, II, III and IV. Introduction of all variables into a linear regression model showed that 3 variables accounted for 51% of the variance in PDQ-39. Mental condition, gait disorders and complications of dopaminergic drugs are the variables that most affect the quality of life of patients with PD.

10 May 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
JZJ. J. Zarranz
J. J. Zarranz
IFI. Ferrer
I. Ferrer
ELE. Lezcano
E. Lezcano
MFM. I. Forcadas
M. I. Forcadas
BEB. Eizaguirre
B. Eizaguirre
Jordi Pérez-TurJordi Pérez-Tur
Jordi Pérez-Tur
Background: Frontotemporal dementia with parkinsonism is often linked to chromosome 17 and is related to mutations in the MAPT gene. In some families the genetic basis is still unknown. The authors report two pedigrees with FTDP-17 harboring a novel mutation (K317M) in exon 11 in the MAPT gene. Methods: The authors identified two apparently unrelated pedigrees with an autosomal dominant neurodegenerative condition. Thirteen patients were examined and eight autopsies were performed. Results: Mean age at onset was 48 years. Mean disease duration was 6 years. Dysarthria often heralded the disease. All cases had parkinsonism and pyramidalism and half of them had amyotrophy. Behavioral or personality changes were not a prominent feature. Cognitive decline appeared late in the evolution. Neuropathologically, a massive degeneration of the substantia nigra without Lewy bodies was a constant finding. A variable degree of frontotemporal atrophy was found. Corticospinal tract degeneration and anterior horn neuron loss were present in six of seven autopsies in which the spinal cord was examined. An extensive deposition of abnormal tau protein in a mixed pattern (neuronal, glial) was observed. Pick’s bodies were not seen. Biochemical analysis of tau revealed two bands of 64 and 68 kDa. Conclusion: Genetic analysis revealed the same novel mutation (K317M) in exon 11 of the MAPT gene in both pedigrees. A common haplotype between members of the two pedigrees suggests that they belong to the same family.